BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26617797)

  • 1. Down-regulation of TET2 in CD3⁺ and CD34⁺ cells of myelodysplastic syndromes and enhances CD34⁺ cells proliferation.
    Zhang W; Shao Z; Fu R; Wang H; Li L; Liu H
    Int J Clin Exp Pathol; 2015; 8(9):10840-6. PubMed ID: 26617797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [TET2 and DLK1 gene expression and their clinical significance in bone marrow CD(3)(+) T cells of patients with myelodysplastic syndrome].
    Zhang W; Fu R; Wang HQ; Li LJ; Yue LZ; Liu H; Qu W; Liang Y; Wang GJ; Wang XM; Wu YH; Liu H; Song J; Guan J; Xing LM; Shao ZH
    Zhonghua Nei Ke Za Zhi; 2012 Jul; 51(7):543-6. PubMed ID: 22943828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes.
    Li X; Marcondes AM; Gooley TA; Deeg HJ
    Blood; 2010 Sep; 116(13):2304-14. PubMed ID: 20562331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [STAT5 phosphorylation in CD34(+)CD38(-)CD123(+) bone marrow cells of the patients with myelodysplastic syndrome].
    Liu BN; Fu R; Wang HQ; Li LJ; Yue LZ; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Wu YH; Song J; Xing LM; Guan J; Wang J; Shao ZH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):480-3. PubMed ID: 22967386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expressions of CD96 and CD123 in Bone Marrow Cells of Patients with Myelodysplastic Syndromes.
    Zhang W; Shao Z; Fu R; Wang H; Li L; Liu H
    Clin Lab; 2015; 61(10):1429-34. PubMed ID: 26642704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Differentiation and expression of membrane hemopoietic cytokine receptors on CD34+ bone marrow cells in patients with myelodysplastic syndromes].
    Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):234-8. PubMed ID: 21418866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on the Characteristics of cell cycle and proliferation of CD34+ hematopoietic stem cells in myelodysplastic syndromes].
    Shi J; Shao ZH; Liu H; Jia HR; Sun J; Bai J; Wu YH; Jing LP; He GS; Cao YR; Wang XL; Tu MF; Hao YS; Yang TY
    Zhonghua Xue Ye Xue Za Zhi; 2004 Nov; 25(11):641-4. PubMed ID: 15634564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes.
    Kalina U; Hofmann WK; Koschmieder S; Wagner S; Kauschat D; Hoelzer D; Ottmann OG
    Exp Hematol; 2000 Oct; 28(10):1158-63. PubMed ID: 11027834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of Fas, FasL and Bcl-2 and apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome].
    Zhang Z; Xie J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):274-7. PubMed ID: 12844412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.
    Scopim-Ribeiro R; Machado-Neto JA; Campos Pde M; Silva CA; Favaro P; Lorand-Metze I; Costa FF; Saad ST; Traina F
    Eur J Haematol; 2015 May; 94(5):413-8. PubMed ID: 25200248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired mutations in TET2 are common in myelodysplastic syndromes.
    Langemeijer SM; Kuiper RP; Berends M; Knops R; Aslanyan MG; Massop M; Stevens-Linders E; van Hoogen P; van Kessel AG; Raymakers RA; Kamping EJ; Verhoef GE; Verburgh E; Hagemeijer A; Vandenberghe P; de Witte T; van der Reijden BA; Jansen JH
    Nat Genet; 2009 Jul; 41(7):838-42. PubMed ID: 19483684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.
    Liu X; Zhang G; Yi Y; Xiao L; Pei M; Liu S; Luo Y; Zhong H; Xu Y; Zheng W; Shen J
    Leuk Lymphoma; 2013 Nov; 54(11):2466-73. PubMed ID: 23432690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Over-expression of cancerous inhibitor of PP2A (CIP2A) in bone marrow cells from patients with a group of high-risk myelodysplastic syndromes.
    Li N; Abe S; Kurata M; Abe-Suzuki S; Onishi I; Kirimura S; Murayama T; Hidaka M; Kawano F; Kitagawa M
    Pathol Oncol Res; 2014 Apr; 20(2):399-407. PubMed ID: 24163288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.
    Scopim-Ribeiro R; Machado-Neto JA; de Melo Campos P; Niemann FS; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F
    Diagn Pathol; 2016 Mar; 11():28. PubMed ID: 26984174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
    Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
    Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
    Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
    Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of BMI1 confers clonal cells resistance to apoptosis and contributes to adverse prognosis in myelodysplastic syndrome.
    Xu F; Yang R; Wu L; He Q; Zhang Z; Zhang Q; Yang Y; Guo J; Chang C; Li X
    Cancer Lett; 2012 Apr; 317(1):33-40. PubMed ID: 22120066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXXC4 mRNA levels are associated with clinicopathological parameters and survival of myelodysplastic syndrome patients.
    Li S; Fan R; Zhao XL; Wang XQ
    Leuk Res; 2014 Sep; 38(9):1072-8. PubMed ID: 25085016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes.
    Sawanobori M; Yamaguchi S; Hasegawa M; Inoue M; Suzuki K; Kamiyama R; Hirokawa K; Kitagawa M
    Leuk Res; 2003 Jul; 27(7):583-91. PubMed ID: 12681357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis in relation to CD34 antigen expression in normal and myelodysplastic bone marrow.
    Pecci A; Travaglino E; Klersy C; Invernizzi R
    Acta Haematol; 2003; 109(1):29-34. PubMed ID: 12486320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.